We report a case of an esophageal ulcer that mimicked advanced esophageal can− cer in a patient who was on alendronate sodium treatment.
A 56−year−old woman presented with progressively worsening pain on swal− lowing. For the past 6 months she had been taking 5 mg/day alendronate so− dium (Bonalon) for the treatment of post− menopausal osteoporosis. Upper gastro− intestinal endoscopic examination re− vealed an ulcerative lesion in the lower esophagus that resembled an advanced esophageal cancer ( Figure 1 ). The ulcers mucosa was normal, but the ulcer bed was uneven and would not stain with Lu− gol dye. Biopsy specimens of the ulcer bed showed a marked infiltration of neutro− phils and eosinophils in the subepithelial space, but no signs of malignancy ( Fig−  ure 2) . We stopped the alendronate so− dium and prescribed a proton−pump inhibitor. Endoscopic examination 2 months later showed marked improve− ment in the ulcer, with no esophageal stricture. This is the first report, to the best of our knowledge, of an alendronate−induced esophageal ulcer mimicking advanced esophageal cancer. Alendronate sodium, a bisphosphonate that inhibits osteoclast activity, is principally used to prevent and treat osteoporosis and is generally considered to be well tolerated. One mul− tinational, randomized, double−blind study, in which postmenopausal women with osteoporosis were treated with alen− dronate for up to 10 years, concluded that the drugs adverse effects on the upper gastrointestinal tract were similar to those of placebo [1] . However, several previously reported cases of severe esophagitis and perforation of the esoph− agus suggest that adverse effects of alen− dronate might be more common than is sometimes recognized [2] .
We should be aware of the possibility of esophageal lesions resulting from the use of bisphosphonates in patients with os− 
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